Time to Gender-Affirming Hormone Therapy Among US Military–Affiliated Adolescents and Young Adults (Q30139)
Jump to navigation
Jump to search
No description defined
- Time to Gender-Affirming Hormone Therapy Among US Military-Affiliated Adolescents and Young Adults.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Time to Gender-Affirming Hormone Therapy Among US Military–Affiliated Adolescents and Young Adults |
No description defined |
|
Statements
Use of exogenous sex steroid hormones, when indicated, may improve outcomes in adolescents and young adults with gender incongruence. (English)
Little is known about factors associated with the time from diagnosis of gender dysphoria to initiation of gender-affirming hormone therapy. (English)
Identification of inequities in time to treatment may have clinical, policy, and research implications. (English)
To evaluate factors associated with time to initiation of gender-affirming hormone therapy after a diagnosis of gender dysphoria in adolescents and young adults receiving care within the US Military Health System. (English)
This retrospective cohort study used TRICARE Prime billing and pharmacy data contained in the Military Health System Data Repository. (English)
DESIGN, SETTING, AND PARTICIPANTS (English)
no value
Patients aged 14 to 22 years, excluding service members and their spouses, who received a diagnosis of gender dysphoria between September 1, 2016, and December 31, 2021, were included. (English)
DESIGN, SETTING, AND PARTICIPANTS (English)
no value
The data were analyzed between August 30 and October 12, 2023. (English)
DESIGN, SETTING, AND PARTICIPANTS (English)
no value
Included patient characteristics were race and ethnicity, age group, first sex assigned in the medical record, and TRICARE Prime sponsor military rank and service at the time of diagnosis. (English)
Health care and contextual characteristics included the year of diagnosis and the primary system in which the patient received health care. (English)
The primary outcome was the time between initial diagnosis of gender dysphoria to the first prescription for gender-affirming hormone medication within a 2-year period. (English)
MAIN OUTCOMES AND MEASURES (English)
no value
A Poisson generalized additive model was used to evaluate this primary outcome. (English)
MAIN OUTCOMES AND MEASURES (English)
no value
Adjusted probability estimates were calculated per specified reference categories. (English)
MAIN OUTCOMES AND MEASURES (English)
no value
Of the 3066 patients included (median [IQR] age, 17 [15-19] years; 2259 with first assigned gender marker of female [74%]), an unadjusted survival model accounting for censoring indicated that 37% (95% CI, 35%-39%) initiated therapy by 2 years. (English)
Age-adjusted curves indicated that the proportion initiating therapy by 2 years increased by age category (aged 14-16 years, 25%; aged 17-18 years, 39%; aged 19-22 years, 55%). (English)
Incidence rate ratios (IRRs) and 2-year adjusted probabilities indicated that longer times to hormone initiation were experienced by adolescents aged 14 to 16 years (IRR, 0.36; 95% CI, 0.30-0.44) and 17 to 18 years (IRR, 0.66; 95% CI, 0.54-0.79) compared with young adults aged 19 to 22 years and Black compared with White adolescents (IRR, 0.73; 95% CI, 0.54-0.99). (English)
Senior officer compared with junior enlisted insurance sponsor rank (IRR, 1.93; 95% CI, 1.04-3.55) and civilian compared with military health care setting (IRR, 1.21; 95% CI, 1.02-1.43) was associated with shorter time to hormone initiation. (English)
In this cohort study, most adolescents and young adults with a diagnosis of gender dysphoria receiving health care through the US military did not initiate exogenous sex steroid hormone therapy within 2 years of diagnosis. (English)
Inequities in time to treatment indicate the need to identify and reduce barriers to care. (English)
Evan R (English)
Locke (English)
ER
Krista B (English)
Highland (English)
KB
Jennifer A (English)
Thornton (English)
JA
Kevin W (English)
Sunderland (English)
KW
Wendy (English)
Funk (English)
W
Veronika (English)
Pav (English)
V
Rick (English)
Brydum (English)
R
Noelle S (English)
Larson (English)
NS
Natasha A (English)
Schvey (English)
NA
Christina M (English)
Roberts (English)
CM
7 October 2024
7 October 2024
<b>Conflict of Interest Disclosures:</b> Dr Roberts reported receiving grants from Organon outside the submitted work. (English)